CORE Biomedicine's therapeutic pipeline targets core lineage-dependent biological pathways that define cancer cell identity, rather than genomic alterations alone. The programs aim to address the drivers of tumor survival and therapy resistance across broader patient populations.

The company launched with oncology assets licensed from Eisai and is advancing its programs toward the clinic with support from its Series A financing and a grant from Japan's Agency for Medical Research and Development.